Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) announced it will host an investor conference call on February 19, 2026, at 3 p.m. Central Time. The call will provide an overview of the company's precision molecular approach to cardiovascular disease prevention and early detection. This approach leverages artificial intelligence to make cardiovascular care more accessible, personalized, and precise.
The conference call will include updates on the company's commercially available tests, Epi+Gen CHD(TM) and PrecisionCHD(TM). These tests are developed using the company's proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, known as its Core Technology. The discussion will also cover recent clinical data, reimbursement progress, and strategic growth initiatives aimed at expanding the reach and impact of its precision cardiovascular medicine solutions.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company. Its mission is to transform the prevention, detection, and management of cardiovascular disease through advanced technology. The company's formation was driven by the goal to further develop and commercialize clinical tests that integrate genetic and epigenetic data using AI. For more information about the company, visit https://cdio.ai/.
The press release was distributed by BioMedWire (BMW), a specialized communications platform focused on the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides extensive wire solutions, article syndication to over 5,000 outlets, enhanced press release services, social media distribution, and tailored corporate communications. For more information about BioMedWire, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
This announcement matters because it highlights ongoing advancements in precision medicine for cardiovascular disease, a leading cause of death globally. The integration of AI with genetic and epigenetic data represents a significant shift toward more proactive and personalized healthcare. By focusing on prevention and early detection, Cardio Diagnostics' approach could potentially reduce the burden of cardiovascular disease on healthcare systems and improve patient outcomes. The investor call will provide insights into the company's progress and future direction, which is important for stakeholders in the healthcare and investment communities. The discussion of reimbursement progress is particularly relevant, as it addresses the practical challenges of integrating new diagnostic technologies into clinical practice and insurance coverage frameworks.
